Navigation Links
New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence of the Significant Role of IL-6 Receptor Inhibition in the Treatment of Rheumatoid Arthritis

BASEL, Switzerland, June 6, 2007-Roche announced today that Toward (1), the second multinational phase III Actemra (tocilizumab) study, successfully reached its primary endpoint and showed that a greater proportion of patients treated with Actemra in combination with traditional disease modifying drugs (DMARDs) achieved a significant improvement in disease signs and symptoms at week 24, compared to the those treated with DMARDs alone. The patients' symptoms were measured using the standard ACR score (2) assessment method. The patients enrolled in the study had active, moderate to severe rheumatoid arthritis (RA) and had experienced an inadequate response to DMARDs.

"The TOWARD trial data further documents the efficacy and safety of Actemra and the value of its IL-6 receptor inhibition. We look forward to further results from this extensive multinational Phase III development programme," commented William Burns, CEO Division Roche Pharmaceuticals.

The TOWARD trial included approximately 40% of patients from the United States and data from this trial will be submitted for presentation at international scientific meetings later this year and in 2008. TOWARD is the second of a programme of five phase III clinical trials running on Actemra, with two other trials due to report later in 2007. In January 2007 Roche reported that OPTION (3), the first of the phase III trials outside Japan, had successfully met its primary endpoint in patients who had an inadequate response to methorexate.

About the TOWARD study The TOWARD (Tocilizumab in cOmbination With traditional DMARD therapy) study was an international study treating 1216 patients with moderate to severe RA. The study was conducted at 130 study sites in 18 countries, including the USA. In th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
4. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
5. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
6. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
7. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
(Date:5/23/2013)... BOSTON , May 23, 2013  PAREXEL International ... it will be presenting at the Jefferies Healthcare Conference ... Vice President and Chief Financial Officer, will be ... at 1:30 p.m. ET on Monday, June 3, 2013. ... available through the "Investors" section of PAREXEL,s website at ...
(Date:5/23/2013)... Mai 2013 Ranbaxy Laboratories ... von Daiichi Sankyo Co., Ltd. (im ... Mai die Maßnahmen bekannt, die Ranbaxy ... um sich der Angelegenheiten der vorhergehenden ... ). Daiichi Sankyo unterstützt ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3PAREXEL International To Present At Jefferies Healthcare Conference 2Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2
... March 23 Magellan Biosciences, Inc., an emerging ... has become the first to offer minocycline and telavancin ... and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC ... negative bacterial isolates, as well as telavancin against Gram ...
... and MORRISTOWN, N.J. , March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, ... be supporting the launch of the new center and its mission of promoting the growth of North Carolina ,s ... ... , , ...
Cached Medicine Technology:FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4
(Date:5/23/2013)... human pathogen that can cause rapidly progressing, life threatening ... "Until now we have not known how it attaches ... mystery how it attaches to the airway to colonise", ... get any symptoms, while some people progress to invasive ... the detail of how the bacterium colonises the airway. ...
(Date:5/23/2013)... Gray HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay ... used to save an infant born with a serious airway ... of bioengineering and surgery. A report in the May ... situation that sparked the innovation. At first, the baby ... to have difficulty breathing and eating when he was 6 ...
(Date:5/23/2013)... 2013 DRE, Inc. is now offering ... a solution to upgrade older model DRE or BFW ... lighting system. , DRE and BFW customers can ... BFW halogen headlights to LED with DRE’s American-made Xavier-C3 ... Conversion Kit provides a bright, clean and even field ...
(Date:5/23/2013)... In Florida, residents have not been hit with a ... Florida’s good luck will continue, warns Rick Knabb, Director of ... residents, it is important to prepare as if one could ... to be a 50-percent chance that a major hurricane could ... from June 1 to November 30 in Florida, this makes ...
(Date:5/23/2013)... The latest report from Insure.com , a leading insurance ... of the country when it comes to auto insurance rates. ... that of the national average of $1,500. Although a variety ... from state to state, there are certain characteristics of Louisianan ... Compared to the rest of the country, according to ...
Breaking Medicine News(10 mins):Health News:New discovery in fight against deadly meningococcal disease 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:Cunningham Financial Group Wants Motorists to Understand Their Rates as Louisiana’s Auto Insurance Rates Remain the Highest in the Nation 2
... , FRIDAY, Aug. 12 (HealthDay News) -- Obstructive sleep apnea ... positive airway pressure (CPAP) machines, a new study finds. ... is interrupted many times during sleep due to the repeated ... by pumping a continuous stream of air through a mask ...
... Joslin Diabetes Center and Children,s Hospital Boston have shown that ... in varying amounts in children increasing until puberty and ... The study used PET imaging data to document children,s ... burns energy instead of storing it. Results were published in ...
... HealthDay Reporter , THURSDAY, Aug. 11 (HealthDay News) -- ... temporary tattoo can pick up and transmit physiological signals such ... new advance in "wearable electronics" might one day replace the ... body functions. "I can,t feel its presence," said John ...
... some past studies have shown that persons carrying a few ... counterparts, a new study that measured subjects, weight at multiple ... Research from Adventist Health Studies recently published in ... that men over 75 with a body mass index (BMI) ...
... , THURSDAY, Aug. 11 (HealthDay News) -- The HIV ... a high prevalence of AIDS is 10 to 20 times ... government report indicates. Two percent of poor heterosexuals in ... Disease Control and Prevention researchers, analysis of National HIV Behavioral ...
... By isolating cells from patients, spinal tissue within a few ... Health have developed a new model of the paralyzing disease ... disease, cells called astrocytes become toxic to nerve cells ... humans. The new model could be used to investigate ...
Cached Medicine News:Health News:'Good fat' most prevalent in thin children 2Health News:Medical Tattoo Tracks Body Functions 2Health News:Medical Tattoo Tracks Body Functions 3Health News:Contrary to earlier findings, excess body fat in elderly decreases life expectancy 2Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:New model of ALS is based on human cells from autopsied tissue 2Health News:New model of ALS is based on human cells from autopsied tissue 3Health News:New model of ALS is based on human cells from autopsied tissue 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: